Search the Newsreel

Merck & Co., Inc. $MRK Shares Purchased by Merit Financial Group LLC

Merit Financial Group LLC increased its stake in Merck & Co., Inc. (NYSE:MRK) by 6.3% in the second quarter, now holding 209,288 shares valued at $26.9 million. This move is part of broader institutional interest, with 76.07% of the stock owned by institutional investors …

Insider Selling: Merck & Co., Inc. (NYSE:MRK) EVP Sells 10,000 Shares of Stock

Merck & Co., Inc. EVP Chirfi Guindo recently sold 10,000 shares of the company's stock for $1.35 million, reducing his direct ownership by over 21%. This sale occurred as MRK shares traded near a 52-week high and the company reported strong quarterly revenues that …

Could Merck & Co., Inc. (MRK) and Gilead Sciences, Inc. (GILD)’s Partnership Create the Next Big Pharma Growth Engine

Two biopharma giants, Merck & Co., Inc. (NYSE:MRK) and Gilead Sciences, Inc. (NASDAQ:GILD), are proving that in modern drug development, the biggest catalyst isn't always competing head-to-head; it is knowing when to join forces. While both companies reported their first-quarter 2026 earnings earlier this …

Merck & Co. (MRK) EVP Chirfi Guindo sells 10,000 common shares

Chirfi Guindo, EVP, Access, Policy & Comms at Merck & Co., Inc. (MRK), sold 10,000 shares of common stock on August 13, 2026, at a price of $135.00 per share. This open market transaction reduced his direct holdings to 36,613.127 shares. The sale, valued …

Merck & Co., Inc. (NYSE:MRK) Reaches New 12-Month High Following Analyst Upgrade

Merck & Co., Inc. (MRK) stock reached a new 52-week high after Daiwa Securities upgraded it to "outperform" with a $143 price target. The company reported strong Q2 revenue of $16.61 billion, exceeding analyst estimates, driven by Keytruda and other oncology products. Despite recent …

Merck & Co. Insider Sold Shares Worth $10,718,495, According to a Recent SEC Filing

A Merck & Co. insider recently sold a significant amount of company shares. This transaction, totaling $10,718,495, was disclosed in a recent SEC filing, indicating a substantial divestment by an insider.

Merck (MRK) EVP Jennifer Zachary exercises options and sells 80,315 shares

Merck's EVP and General Counsel, Jennifer Zachary, exercised stock options for a total of 54,927 shares and subsequently sold 80,315 common shares on August 12, 2026. The shares were sold at a weighted average price of $133.4557, totaling approximately $10.72 million in gross proceeds. …

Merck (MRK) Stock Fair Value Edges Higher After Analysts Back Pipeline Progress

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Price target commentary for Merck has shifted toward a US$140 to US$155 range, anchored by a modest uplift in fair value from US$132.78 to …

Merck (MRK) Stock Looks Fully Valued Following Raised Revenue Outlook

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Merck stock has almost doubled investors' money over the past five years, yet there …

Can Keytruda Sustain Merck's Growth in the Second Half of 2026?

Merck's MRK strong foothold in the oncology space is backed by its biggest revenue driver, Keytruda. The blockbuster PD-L1 inhibitor alone accounts for more than 55% of the company's total pharmaceutical sales. In the United States, Keytruda is approved for 44 indications spanning 19 …

Prevail Innovative Wealth Advisors LLC Raises Holdings in Merck & Co., Inc. $MRK

Prevail Innovative Wealth Advisors LLC increased its stake in Merck & Co., Inc. by 45.0% during the second quarter, bringing its total holdings to 29,458 shares valued at $3,785,000. Several other institutional investors also adjusted their positions in MRK, contributing to a total institutional …

Merck's planned $11.3B acquisition of Bio-Techne moves forward

Bio-Techne reported Q4 FY2026 net sales of $321.2 million, a 1% increase (3% organically), with GAAP EPS of $0.35 and adjusted EPS of $0.52. The full fiscal year 2026 saw flat revenue at $1.2 billion, but GAAP EPS increased to $1.16 and adjusted EPS …

5 Insightful Analyst Questions From Merck’s Q2 Earnings Call

5 Insightful Analyst Questions From Merck's Q2 Earnings Call Merck's second quarter was marked by continued sales growth, primarily driven by the strength of its oncology portfolio and contributions from new product launches. Management credited higher demand for KEYTRUDA in both early-stage and metastatic …

Merck & Co., Inc. (NYSE:MRK) EVP Richard Deluca Sells 11,699 Shares of Stock

Merck & Co., Inc. EVP Richard Deluca recently sold 11,699 shares of the company's stock for approximately $1.54 million, reducing his stake by 9.6%. This sale follows strong quarterly results where Merck exceeded revenue and adjusted EPS estimates and maintained positive fiscal year 2026 …

Merck & Co. (MRK) EVP Richard DeLuca sells 45,320 shares over three days

Richard R. DeLuca, EVP & President, Merck Animal Health, sold a total of 45,320 shares of Merck & Co. common stock over three days (August 10-12, 2026). The sales were open-market or private transactions, with weighted average prices ranging from $130.0000 to $132.6514. These …

Merck & Co., Inc. (NYSE:MRK) Upgraded at Daiwa Securities Group

Daiwa Securities Group upgraded Merck & Co., Inc. (NYSE:MRK) from "neutral" to "outperform" with a $143 price target. This upgrade comes as Merck reported strong quarterly revenue of $16.61 billion, exceeding estimates, and adjusted EPS of $(0.13), also beating consensus. Despite favorable analyst sentiment …

Remepy Raises $36 Million Series A to Expand Its Hybrid Drug™ Pipeline Through Pharmaceutical Partnerships and Advance Phase III of Hybridopa™ for Parkinson's Disease

Funding brings total capital raised to $62 million as the Company expands pharmaceutical co-development partnerships and accelerates the Hybrid Drug category NEW YORK, Aug. 12, 2026 /PRNewswire/ -- Remepy, the pioneer of Hybrid Drugs, today announced the closing of a $36 million Series A …

Daiwa Upgrades Merck & Co. to Outperform From Neutral, Adjusts PT to $143 From $120

Daiwa has upgraded Merck & Co. (MRK) from a "Neutral" rating to an "Outperform" rating, significantly increasing its price target to $143 from the previous $120. The article, published on MarketScreener, highlights this analyst recommendation as a key news item for the pharmaceutical company. …

Merck & Company, Inc. Stock 12‑Month Price Target Raised to $138.29, Implies 6% Upside

Merck & Company, Inc. (MRK) has seen its average 12-month price target raised from $137.56 to $138.29 by 24 analysts, indicating a potential 6% upside from its Aug. 11 closing price. The consensus rating for the stock remains "Buy" among 29 analysts, with a …

Merck (MRK) Wins FDA And EMA Review For Broader RSV Use In Children

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Merck (NYSE:MRK) said the FDA and EMA have accepted supplemental applications to expand ENFLONSIA for preventing RSV in young children at elevated risk. …

MRK Stock Up 5.6% in a Month as Estimates Fall: Buy, Hold or Sell?

Merck's MRK stock is up 5.6% in a month. The key reason for the increase was the strong second-quarter 2026 performance. Merck beat estimates for both earnings and sales in the second quarter. Revenues in the second quarter increased 5% to $16.61 billion as …

Argus Issues Positive Forecast for Merck & Co., Inc. (NYSE:MRK) Stock Price

MERCK & CO INC : ARGUS RESEARCH RAISES TARGET PRICE TO $145 FROM $130

Argus Research has increased its target price for Merck & Co Inc (MRK.N) to $145 from $130. This update reflects the analyst's revised valuation for the pharmaceutical company. The article attributes this information to Reuters.

Argus Adjusts Price Target on Merck & Co. to $145 From $130, Keeps Buy Rating

Argus has raised its price target for Merck & Co. (MRK) to $145 from $130, while maintaining a Buy rating on the stock. The adjustment reflects a positive outlook for the pharmaceutical company. This news was published on August 11, 2026, at 08:57 am …

KMG Fiduciary Partners LLC Sells 26,888 Shares of Merck & Co., Inc. $MRK

KMG Fiduciary Partners LLC significantly reduced its stake in Merck & Co., Inc. (NYSE:MRK) by selling 26,888 shares, a 50.5% decrease, now holding 26,379 shares valued at $3.39 million. Despite this, institutional investors collectively own 76.07% of Merck's stock, and analysts maintain a "Moderate …

Carolina Wealth Advisors LLC Sells 15,954 Shares of Merck & Co., Inc. $MRK

Carolina Wealth Advisors LLC reduced its stake in Merck & Co., Inc. (NYSE:MRK) by 33.2% in the second quarter, selling 15,954 shares and now owning 32,171 shares valued at $4.13 million. The article also details other institutional investor activity, Merck's financial performance including its …

Bay Colony Advisory Group Inc d b a Bay Colony Advisors Trims Stake in Merck & Co., Inc. $MRK

Bay Colony Advisory Group Inc d b a Bay Colony Advisors reduced its stake in Merck & Co., Inc. by 33.4% in the second quarter, selling 10,387 shares and holding 20,685 shares valued at $2,658,000. Despite this reduction, other institutional investors increased their holdings, …

Merck (MRK) animal health chief DeLuca sells 6,050 shares

Richard R. DeLuca, EVP & President of Merck Animal Health, sold a total of 6,050 shares of Merck & Co., Inc. common stock on August 6, 2026. The sales occurred in three separate open-market transactions at weighted-average prices between $130 and $131 per share. …

Merck & Co. Inc. stock outperforms competitors on strong trading day

Merck & Co. Inc. (MRK) stock rallied 1.82% to $130.92 on a generally down day for the market, marking its fifth consecutive day of gains. The S&P 500 Index and Dow Jones Industrial Average both saw slight declines. This performance highlights Merck's strength relative …

Eikon Therapeutics adds Merck chemistry head to advisory board

Eikon Therapeutics has appointed Johnny Bennett, Ph.D., Merck Research Laboratories' Vice President and Head of Discovery Chemistry, to its Scientific Advisory Board. This appointment strengthens the existing collaboration between Eikon and Merck, which includes Merck supplying KEYTRUDA for Eikon's clinical trials and participating in …

Merck & Co., Inc. $MRK Shares Sold by Rockland Trust Co.

Rockland Trust Co. reduced its stake in Merck & Co., Inc. by 8.4% in the second quarter, selling 44,914 shares while still holding 490,049 shares valued at $63 million. Despite this, other institutional investors increased their positions, and institutions collectively own 76.07% of the …

3rd Circ. Says Pharma Co. Suit Against Merck Belongs In India

The Third Circuit has ruled that a legal dispute between pharmaceutical giant Merck and a now-defunct Indian pharmaceutical company must be litigated in India. The case revolves around a terminated business relationship between the two entities. This decision establishes the proper jurisdiction for the …

Ebola response turns to Merck vaccine, Gilead drug as Congo outbreak worsens

The Ebola response in eastern Democratic Republic of Congo is intensifying, with plans to expand the use of Merck & Co.'s Ebola vaccine, Ervebo, and Gilead Sciences Inc.'s antiviral drug, remdesivir. This comes as the current Bundibugyo strain outbreak, which has caused nearly 4,000 …

Merck & Co. Insider Sold Shares Worth $6,805,145, According to a Recent SEC Filing

A recent SEC filing revealed that Caroline L. Sweeney, an insider at Merck & Co. (NYSE:MRK), sold 54,775 shares of the company's stock for a total value of $6,805,145. This transaction occurred on August 6, 2026, with shares sold at an average price of …

Insider Selling: Merck & Co., Inc. (NYSE:MRK) EVP Sells 52,847 Shares of Stock

Merck & Co., Inc. EVP David Michael Williams sold 52,847 shares of company stock for approximately $6.81 million, significantly reducing his direct ownership. The company reported strong quarterly results, exceeding revenue and EPS estimates, and declared an $0.85 quarterly dividend. Analysts maintain a "Moderate …

Merck (MRK) tech chief exercises 52,847 stock options, sells all shares

David Michael Williams, EVP and Chief Information & Digital Officer at Merck & Co., Inc. (MRK), exercised 52,847 stock options on August 5, 2026, at various strike prices. He subsequently sold all 52,847 shares at a weighted average price of $128.7707, generating approximately $2.87 …